Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 10/20 | 0.71 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.71 |
| ▸ | CLCN2 | P51788 | 7/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | TTR | P02766 | 2/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | PGR | P06401 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.69 |
| ▸ | AR | P10275 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3500411 | 0.89 | FTO (0.72) | FTOPBRM1CLCN2MEN1TTR | |
| SCHEMBL24021600 | 0.86 | FTO (0.77) | FTOCLCN2TTR | |
| SCHEMBL11518282 | 0.86 | PTGS2 (0.56) | FTOPBRM1CLCN2MEN1TTR | |
| SCHEMBL374772 | 0.86 | PTGS2 (0.55) | FTOPBRM1CLCN2MEN1TTR | |
| SCHEMBL4249088 | 0.85 | PBRM1 (0.75) | FTOPBRM1CLCN2MEN1TTR | |
| SCHEMBL30575470 | 0.85 | PBRM1 (0.75) | FTOPBRM1CLCN2MEN1TTR | |
| SCHEMBL11407549 | 0.84 | CXCL8 (0.55) | FTOPBRM1CLCN2MEN1TTR | |
| Clofenamic Acid SCHEMBL1477650 | 0.84 | PBRM1 (0.73) | FTOPBRM1CLCN2MEN1TTR | |
| Clofenamic Acid SCHEMBL29900200 | 0.84 | PBRM1 (0.73) | FTOPBRM1CLCN2MEN1TTR | |
| SCHEMBL28297347 | 0.84 | PBRM1 (0.73) | FTOPBRM1CLCN2MEN1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108047068-A | A kind of synthetic method of C14H10Cl2NNaO2 impurity B | 河南中帅医药科技股份有限公司 | 2018-05-18 | — | — | CN | claimed |
| JP-55108845-A | — | — | None | — | — | JP | disclosed |
| JP-56079651-A | — | — | None | — | — | JP | disclosed |
| CN-111808011-B | High penetration composition and its application | 泰飞尔生物医药(苏州)有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-109553544-B | Method for synthesizing diclofenac sodium | 浙江普利药业有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11173137-B2 | Compositions and methods to modulate chloride ion channel activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-11-16 | — | — | US | disclosed |
| CN-102164594-B | Use of anti-connexin agents for modulating the efficacy of psychotropic drug molecules | 原子能和替代能源委员会 | 2021-09-28 | — | — | CN | disclosed |
| CN-113402408-A | Method for synthesizing diclofenac sodium | 河南康达制药有限公司 | 2021-09-17 | — | — | CN | disclosed |
| WO-2020037294-A1 | SYSTEM AND METHOD FOR BIPHASIC TRANSDERMAL IONTOPHORETIC DELIVERY OF DICLOPHENAC AND OTHER THERAPEUTIC AGENTS | INCUBE LABS, LLC (US) | 2020-02-20 | — | — | WO | disclosed |
| CN-109553544-A | A kind of synthetic method of C14H10Cl2NNaO2 | 浙江普利药业有限公司 | 2019-04-02 | — | — | CN | disclosed |
| US-5112846-A | Nonsteroidal antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1992-05-12 | — | — | US | disclosed |
| US-5075330-A | N-hydroxyamide, N-hydroxythioamide, N-hydroxyurea, and N-hydroxythiourea derivatives of selected NSAIDS as antiinflammatory agents | WARNER-LAMBERT CO. (US) | 1991-12-24 | — | — | US | disclosed |
| US-4981865-A | N-hydroxyamide, N-hydroxythioamide, hydroxyurea, and N-hydroxythiourea derivatives of selected nsaids as antiinflammatory agents | WARNER-LAMBERT CO. (US) | 1991-01-01 | — | — | US | disclosed |
| EP-0316630-A1 | Novel fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition | WARNER-LAMBERT COMPANY (US) | 1989-05-24 | — | — | EP | disclosed |
| WO-1989003818-A1 | NOVEL FENAMIC ACID HYDROXAMATE DERIVATIVES HAVING CYCLOOXYGENASE AND 5-LIPOXYGENASE INHIBITION | WARNER-LAMBERT COMPANY (US) | 1989-05-05 | — | — | WO | disclosed |
| JP-S5679651-A | PREPARATION OF BENZALDEHYDE DERIVATIVE | PAAMAKEMU ASIA:KK | 1981-06-30 | — | — | JP | disclosed |
| US-4242522-A | O-(N-Allyl-2,6-dichloroanilino)phenylacetic acid derivative and a process for preparing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1980-12-30 | — | — | US | disclosed |
| JP-S55108845-A | PREPARATION OF SUBSTITUTED PHENYLACETIC ACID DERIVATIVE | PAAMAKEMU ASIA:KK | 1980-08-21 | — | — | JP | disclosed |
| US-4189595-A | [N-benzyl-o-(2,6-dichloroanilino)phenyl]acetic acid derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1980-02-19 | — | — | US | disclosed |
| US-4188343-A | Process for preparing anthranylaldehyde derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1980-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11173137-B2 | Compositions and methods to modulate chloride ion channel activity | CLCN2, CLIC1, CLIC4 | FTO 4582/4885PBRM1 3615/4885CLCN2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.